Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)

#2699

Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.

Aim(s): The objective of this study was to evaluate efficacy and tolerance of Dacarbazine- or Temozolomide-based chemotherapy in metastatic digestive NEC in post first-line chemotherapy.

Materials and methods: This study included patients with a metastatic NEC of digestive or unknown primary. All of them received platinum-etoposide in first-line chemotherapy. The primary endpoint was progression free survival (PFS). Secondary endpoints were: clinical/biological (ALP decrease >30%)/morphological (RECIST) response, toxicity, and overall survival (OS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Walter T

Authors: Couronne T, Fine C, Hadoux J, Lecomte T, Lorcet M,

Keywords: neuroendocrine, poorly differentiated neuroendocrine tumour, neuroendocrine carcinoma, chemotherapy, temozolomide, dacarbazine,